Novo Nordisk sues Eli Lilly over weight-loss drug ads

Novo Nordisk has filed a lawsuit against Eli Lilly, accusing the company of false and misleading advertising concerning its weight-loss drugs. This high-stakes legal conflict focuses on the marketing of GLP-1 medications. Novo Nordisk claims that Eli Lilly utilized deceptive advertising practices to promote its products. The legal action highlights the intense competition between these pharmaceutical giants as they vie for dominance within the weight-loss drug market through aggressive and contested promotional strategies.